Hydroxychloroquine reduces microglial activity and attenuates experimental autoimmune encephalomyelitis

Area of Science:

• Neuroimmunology
• Pharmacology

Background:

• Microglial activation is central to multiple sclerosis (MS) pathogenesis.
• Hydroxychloroquine (HCQ), an antimalarial drug, possesses immunomodulatory effects.
• This study investigates HCQ's impact on microglial activation and experimental autoimmune encephalitis (EAE).

Purpose of the Study:

• To evaluate the effect of HCQ on human microglial activation in vitro.
• To assess HCQ's efficacy in preventing or delaying the development of EAE in vivo.

Main Methods:

• Human microglia were activated with lipopolysaccharide (LPS).
• Cytokine production in HCQ-treated and untreated microglia was measured.
• HCQ's effect on EAE development and spinal cord pathology was assessed in mice.

Main Results:

• HCQ significantly reduced pro-inflammatory (TNF-α, IL-6, IL-12) and anti-inflammatory (IL-10, IL-1 receptor antagonist) cytokine production by LPS-stimulated microglia.
• HCQ pretreatment delayed EAE onset in mice.
• Reduced microglial/macrophage infiltration and demyelination were observed in HCQ-treated animals' spinal cords.

Conclusions:

• HCQ effectively suppresses human microglial activation in vitro.
• HCQ demonstrates neuroprotective effects by delaying EAE and reducing spinal cord pathology.
• HCQ is a promising candidate for clinical investigation in multiple sclerosis therapy.